Healthcare
Shattuck Labs, Inc.(STTK)
Live Price
Offline$4.95
+4.43% today
1Y Change
+352.46%
Window
Jun 20, 2025 โ Jun 16, 2026
- Market Cap
- $330.00M
- Revenue Growth
- -82.5%
- EPS Growth
- +53.0%
- Dividend Yield
- 0.0%
Coverage: 248 bars ยท Jun 20, 2025 โ Jun 16, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Shattuck Labs, Inc. (STTK) is a Healthcare stock with a market cap of $330.00M and listed on NASDAQ. The stock last traded around $4.95 and up 352.5% across the available one-year price window (Jun 20, 2025 โ Jun 16, 2026). Baseline metrics include revenue growth of -82.5%, EPS growth of +53.0%, a dividend yield of 0.0%. What stands out right now is revenue -82.5%, EPS +53.0%, free cash flow +34.0% with operating margin -5142.7% and ROIC -61.2%. Valuation already assumes a fairly strong business story at price/sales 334.8. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines STTK price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-82.5% vs +7.6% peer median
Operating Margin
Below sector median
-5142.7% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 7, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -82.5% and EPS is at +53.0%, with operating margin around -5142.7%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +6.9% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 7, 2026 | โ | +9.4% | +6.5% | -26.8% |
2026 Mar 5, 2026 | +0.0% | +17.5% | +20.2% | +25.9% |
2025 Nov 6, 2025 | +6.7% | +1.0% | -6.1% | +58.2% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
STTK
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
STTK Max Drawdown
-50.51%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for STTK and SPY.
Company Overview
Shattuck Labs, Inc.
NASDAQ Global Select
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also develops SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was incorporated in 2016 and is headquartered in Austin, Texas.
- Leadership
- Taylor H. Schreiber
- IPO Date
- Oct 9, 2020
- Employees
- 44
- Street Address
- 500 West 5th Street
- Mailing
- Austin, TX, 78703
- Region
- Austin, TX, US
- Reporting Currency
- USD
- Investor Line
- 512 900 4690
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 334.8
- Price/Book
- 8.8
Growth
- Revenue
- -82.5%
- EPS
- +53.0%
- Free Cash Flow
- +34.0%
Profitability
- Gross Margin
- -177.1%
- Operating Margin
- -5142.7%
- Net Margin
- -4880.9%
- ROE
- -65.0%
- ROIC
- -61.2%
Balance Sheet
- Debt/Equity
- 0.02
- Current Ratio
- 11.70
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.